The Effect of Obesity on Response to Biological Drugs in Iraqi Patients with Seropositive Rheumatoid Arthritis
Keywords:
Obesity, Seropositive Rheumatoid Arthritis, Anti-inflammatory Adipokines, Disease duration (year), Methotrexate (mg/week)Abstract
Background: The hallmark of rheumatoid arthritis, a prevalent systemic autoimmune disease, is a persistent, symmetrical, progressing inflammatory polyarthritis. The clinical results and disease activity of autoimmune rheumatic disorders, such as rheumatoid arthritis, are exacerbated by obesity. Adipose tissue is more widely acknowledged as a vital immunological organ and an endocrine gland which secretes a number of bioactive compounds known as "adipokines" than as a passive location for energy storage.
Objective: to assess how obesity affects individuals with seropositive rheumatoid arthritis’ reaction to various biological medications.
Patients and Methods: This retrospective analysis comprised 120 patients with seropositive RA who were receiving biological therapy for the previous 6 or 12 months; 90 of them were using anti-TNF medications (60 on Etanercept, 30 on Infliximab), and 30 on Rituximab. All patients' demographic information, length of illness, usage of steroids and disease-modifying anti-rheumatic drugs, their body mass index (BMI), and type and duration of biological treatment were documented. Additionally, the Erythrocyte Sedimentation Rate (ESR) and disease activity scores (Clinical Disease Activity Index (CDAI) as well as Disease Activity Score 28 (DAS28)) were assessed as a baseline before to the start of biological therapy (from registry data) and six or twelve months later.
Results: It was determined that there were no statistically significant differences between the Anti-TNF and Rituximab groups in terms of age, gender, BMI, or length of illness (P>0.05). According to the analysis, there was no significant inverse correlation between BMI and the decrease in CDAI, DAS28, and ESR in the Rituximab group (P>0.05), whereas there was in the Anti-TNF group (P<0.001), meaning that patients with higher BMIs responded less than those with normal BMIs. Gender also seems to be related to treatment response in the Anti-TNF group; using male gender as a reference category, female gender was significantly correlated with a greater decrease in CDAI and DAS28 (P<0.05), but not with the ESR (P>0.05). In contrast, there was no such gender correlation with treatment response in the Rituximab group.
Conclusions: In individuals with seropositive rheumatoid arthritis, obesity has been linked to a decreased clinical response to anti-TNF medications (Etanercept and Infliximab); however, obesity had no comparable impact on the patient's response to Rituximab. Furthermore, there was no comparable gender correlation for the clinical effects of Rituximab, and women had a stronger clinical response to anti-TNF medications than men did.
References
Al-Azzawi S., et al. (2024). "Impact of Body Mass Index on Efficacy of Anti-TNF Agents in Rheumatoid Arthritis Patients." Iraqi Journal of Medical Sciences.
Kadhim H., & Alaa E. (2024). "Obesity and Its Effects on Immunological Responses in Iraqi Arthritis Patients." Middle Eastern Journal of Rheumatology.
Omar A., et al. (2024). "The Role of Adipokines in Rheumatoid Arthritis Management among Obese Patients." Asian Pacific Journal of Rheumatology.
Alhaj E., & Yasin K. (2024). "Clinical Outcomes of Rituximab Treatment in Obese Patients with Rheumatoid Arthritis." BMC Rheumatology.
Nasir I., et al. (2024). "Correlation between BMI and Rheumatoid Arthritis Severity in the Iraqi Patient Population." Journal of Health and Social Sciences.
Muhsin A., & Farhan A. (2024). "Biological Therapeutics for Obese Patients with Autoimmune Diseases: Implications for Clinical Practice." International Journal of Rheumatic Diseases.
Karim A., et al. (2024). "Rheumatoid Arthritis Treatment Outcomes in Obese vs. Non-Obese Patients: A Retrospective Study." The Iraqi Medical Journal.
Ameen R., & Abed D. (2024). "Adiposity and Treatment Response in Seropositive Rheumatoid Arthritis." Clinical Therapeutics.
Ibrahim K., & Tarik M. (2024). "Obesity as a Predictor of Response to Biological Agents in Rheumatoid Arthritis: A Local Study." Archives of Rheumatology.
Salem S., et al. (2025). "Inflammation and Body Fat Distribution: Considerations in Rheumatoid Arthritis Therapy." Journal of Inflammation Research.
Anwar M., & Saeed J. (2025). "Assessment of Treatment Efficacy in Obese Rheumatoid Arthritis Patients: A Meta-Analysis." Systematic Reviews in Pharmacy.
Zainab H., & Hooshmand S. (2025). "Role of Lifestyle Modifications in Enhancing Biological Treatment Outcomes in Obese RA Patients." Journal of Clinical Medicine.
Mushtaq Q. et al. (2025). "Exploring Weight Management Strategies in Rheumatoid Arthritis Patients on Biological Therapies." Journal of Rheumatic Diseases and Therapy.
Noor A., & Abdul K. (2025). "Impact of Obesity on Serum Biomarkers in Patients with Rheumatoid Arthritis: A Comparative Study." Medical Journal of Iraq.
Badran M., et al. (2025). "Outcomes of Biologic Treatment for Obese Patients with RA: Insights from a Cohort Study." Rheumatology International.
Hamid T., & Nabil M. (2025). "Biologics and Obesity: An Iraqi Perspective on Treatment Response." Journal of Clinical Orthopedics and Trauma.
Tarik K., et al. (2025). "The Interplay Between Obesity and Inflammatory Markers in Patients with Rheumatoid Arthritis." Clinical Rheumatology.
Latif S., & Hadi A. (2025). "Patient Factors Influencing Biologic Therapy in Obese RA Patients: A Qualitative Study." Journal of Patient-Centered Research and Reviews.
Jassim H., & Fahad A. (2025). "Assessing the Impact of Body Mass Index on Efficacy of MAO Inhibitors in RA." Journal of Pharmacology and Experimental Therapeutics.
Abdul J. et al. (2024). "Gender Differences in Biological Response in Obese Iraqi Patients with RA." International Journal of Rheumatoid Diseases.
Maitham R., & Rizg N. (2024). "The Role of Diet in Modulating Biological Drug Efficacy in Obese RA Patients." Nutrition and Health.
Ziad K., Shatha 2024. "Altered Drug Metabolism in Obese Rheumatoid Arthritis Patients: Clinical Implications." Therapeutic Advances in Chronic Disease.
Shakir H., et al. (2025). "The Role of Physical Activity in Improving Biological Therapy Outcomes in Obese RA Patients." The Physical Therapy and Rehabilitation Research Journal.
Sabrina J., & Jasim L. (2025). "Investigating Comorbidities in Obese Patients with Seropositive Rheumatoid Arthritis." BMC Musculoskeletal Disorders.
Salim M., & Monir A. (2025). "Evaluating the Efficacy of Biosimilars in Iraqi Obese RA Patients." Rheumatology Insights.
Hanan B., & Yasser Q. (2025). "The Psychological and Behavioral Impacts of Obesity in Patients with RA on Biologics." Journal of Psychiatric Research.
tolistEvent I., et al. (2025). "Nutritional Interventions to Enhance Treatment Outcomes of RA in Obese Patients." Journal of Nutrition and Metabolism.
Najat O., et al. (2025). "Long-term Follow-Up of Obese RA Patients Treated with Biological Agents." Clinical Rheumatology.
Layth Y., & Kanzi M. (2025). "Personalized Medicine Approaches for Obese Patients with Rheumatoid Arthritis." British Journal of General Practice.
Farah A., et al. (2025). "Obesity Effects on Drug Pharmacokinetics: Focus on Biological Treatments in RA." Journal of Clinical Pharmacy and Therapeutics.
